Communiqués Janux Therapeutics, Inc.

Actions

JANX

US47103J1051

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 05/10/2026			Varia. 5j.	Varia. 1 janv.
16,54 ^USD	-2,30%		-0,24%	+19,86%

14/09	Janux Therapeutics administre la première dose dans l'étude de phase 1 de son candidat contre le cancer de la prostate	MT
14/09	Janux Therapeutics administre la première dose au premier patient de l'étude de phase 1 sur le JANX013 en association avec le JANX007 pour le cancer de la prostate métastatique résistant à la castration	CI

Communiqués

14/09	Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013	BU
06/08	Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights	BU
08/05	Janux Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights	BU
27/04	Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development	BU
16/04	Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014	BU
01/04	Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment	BU
26/02	Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights	BU
17/02	Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011	BU
26/01	Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer	BU
22/01	Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors	BU
23/12	Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study	BU
01/12	Janux Therapeutics : JANX007 Clinical Data Update	PU
01/12	Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC	BU
24/11	Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC	BU
06/11	Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights	BU
07/08/25	Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights	BU
05/08/25	Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck	BU
24/07/25	Janux Therapeutics : R&D Day Presentation	PU
24/07/25	Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day	BU
17/07/25	Janux Therapeutics to Host Virtual R&D Day on July 24, 2025	BU
15/05/25	Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer	BU
08/05/25	Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights	BU
05/05/25	Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates	BU
27/02/25	Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights	BU